Regarding the second-line therapy to ITP, one patient in the HS group failed in treatment with rituximab, recombinant human thrombopoietin (rhTPO), eltrombopag, and mycophenolate mofetil, while the other in this group achieved complete remission after combination therapy of rituximab, rhTPO, eltrombopag, and high-dose dexamethasone. This evidence concerns the gene THPO and autoimmune thrombocytopenic purpura.